Overview

Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, parallel-group, single-dose study of lofexidine in 8 adult subjects with ESRD maintained on hemodialysis (3 times per week) and 8 control subjects with normal renal function, recruited as 1:1 matches to each ESRD subjects, matched for gender, age, and BMI.
Phase:
Phase 1
Details
Lead Sponsor:
US WorldMeds LLC
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Clonidine
Lofexidine